Toll-like Receptors Signaling Pathways as a Potential Therapeutic Target in Cardiovascular Disease

Author:

Parizadeh Seyed Mostafa1,Ghandehari Maryam1,Heydari-majd Motahareh1,Seifi Sima1,Mardani Ramin1,Parizadeh Seyed Mohamadreza1,Ghayour-Mobarhan Majid1,Ferns Gordon A.2,Hassanian Seyed Mahdi1,Avan Amir1

Affiliation:

1. Metabolic syndrome Research center, Mashhad University of Medical Sciences, Mashhad, Iran

2. Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, United Kingdom

Abstract

Cardiovascular Disease (CVD) is one of the most important causes of morbidity and mortality, and associated with an important economic burden globally. Over the last decade, the prevalence of CVD has been rising globally, and is now associated with millions of death annually in both developed and developing countries. There is good evidence that the immune system is involved in the pathophysiology of CVD. Toll-like receptors (TLRs) and their down-stream signaling pathways play an important role in the immune system. Recent studies have suggested that the TLRs are involved in atherogenesis, including stroke, myocardial infarction, ischemiareperfusion injury, cardiac remodeling and development of Heart Failure (HF). In this review we have summarized the recent studies investigating the role of TLRs in CVD and the potential for using TLRs signaling pathways as a therapeutic target in CVD.

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Pharmacology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3